Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 436,715	$ 541,835
Accounts receivable, net of allowances of approximately $3.2 million and $2.9 million at March 31, 2017 and December 31, 2016, respectively	22,538	22,087
Inventory, net	71,707	70,898
Prepaid expenses and other current assets	15,356	19,133
Total current assets	546,316	653,953
Fixed assets, net	30,794	30,961
Indefinite-lived intangible assets, net	253,620	253,620
Finite-lived intangible assets, net	355,132	361,601
Goodwill	255,629	255,629
Restricted cash	5,037	5,032
Contingent purchase price from sale of businesses	143,700	143,700
Other assets	724	715
Total assets	1,590,952	1,705,211
Current liabilities:
Accounts payable	17,529	28,450
Accrued expenses	63,303	88,524
Current portion of contingent purchase price	45,508	55,000
Convertible senior notes	381,892	53,749
Deferred revenue	18,641	18,902
Total current liabilities	526,873	244,625
Contingent purchase price	79,227	82,289
Convertible senior notes	302,414	623,584
Deferred tax liabilities	89,992	89,992
Other liabilities	11,258	11,705
Total liabilities	1,009,764	1,052,195
Equity component of currently redeemable convertible senior notes	65,372	1,033
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 187,500,000 authorized; 74,306,937 issued and 72,113,955 outstanding at March 31, 2017 and 73,212,545 issued and 71,019,563 outstanding at December 31, 2016	74	73
Additional paid-in capital	1,223,202	1,256,890
Treasury stock, at cost; 2,192,982 shares at March 31, 2017 and December 31, 2016	(50,000)	(50,000)
Accumulated deficit	(651,653)	(548,983)
Accumulated other comprehensive loss	(5,807)	(5,479)
Total The Medicines Company stockholders’ equity	515,816	652,501
Non-controlling interest in joint venture	0	(518)
Total stockholders’ equity	515,816	651,983
Total liabilities and stockholders’ equity	1,590,952	1,705,211
Product licenses, net
Current assets:
Finite-lived intangible assets, net	26,214	26,987
Developed product rights, net
Current assets:
Finite-lived intangible assets, net	328,918	334,614
In-process research & development
Current assets:
Indefinite-lived intangible assets, net	$ 253,620	$ 253,620